Patents by Inventor Li-sheng Lu
Li-sheng Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250107207Abstract: A semiconductor structure includes a semiconductor substrate; fin active regions protruded above the semiconductor substrate; and a gate stack disposed on the fin active regions; wherein the gate stack includes a high-k dielectric material layer, and various metal layers disposed on the high-k dielectric material layer. The gate stack has an uneven profile in a sectional view with a first dimension D1 at a top surface, a second dimension D2 at a bottom surface, and a third dimension D3 at a location between the top surface and the bottom surface, and wherein each of D1 and D2 is greater than D3.Type: ApplicationFiled: December 9, 2024Publication date: March 27, 2025Inventors: Chi-Sheng LAI, Wei-Chung SUN, Yu-Bey WU, Yuan-Ching PENG, Yu-Shan LU, Li-Ting CHEN, Shih-Yao LIN, Yu-Fan PENG, Kuei-Yu KAO, Chih-Han LIN, Jing Yi YAN, Pei-Yi LIU
-
Publication number: 20250081255Abstract: The present disclosure discloses a Bluetooth communication system. A first access point apparatus of a Bluetooth access point apparatus performs periodic broadcast communication.Type: ApplicationFiled: August 29, 2024Publication date: March 6, 2025Inventors: CHIA-CHUN HUNG, Li-Ya Huang, Hsin-Yu Chang, Yu Chiang, Po-Sheng Chiu, Yu-Hsin Lu
-
Patent number: 12110337Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.Type: GrantFiled: April 3, 2019Date of Patent: October 8, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Li-Sheng Lu, Mark J. Selby, Alan J. Korman, Shrikant Deshpande, Mohan Srinivasan, Jun Zhang, Haichun Huang, Guodong Chen, Richard Y. Huang, Ekaterina Deyanova
-
Publication number: 20210155703Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.Type: ApplicationFiled: April 3, 2019Publication date: May 27, 2021Inventors: Li-Sheng Lu, Mark J. Selby, Alan J. Korman, Shrikant Deshpande, Mohan Srinivasan, Jun Zhang, Haichun Huang, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Patent number: 9988453Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: GrantFiled: February 19, 2016Date of Patent: June 5, 2018Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison J. Witte, Haichun Huang
-
Patent number: 9505845Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: GrantFiled: April 9, 2012Date of Patent: November 29, 2016Assignee: E. R. Squibb & Sons, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
-
Publication number: 20160168249Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: E.R. SQUIBB & SONS, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison J. Witte, Haichun Huang
-
Patent number: 9296822Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: GrantFiled: November 7, 2013Date of Patent: March 29, 2016Assignee: E.R. SQUIBB & SONS, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison J. Witte, Haichun Huang
-
Patent number: 9217033Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.Type: GrantFiled: February 10, 2014Date of Patent: December 22, 2015Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
-
Patent number: 9102738Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: GrantFiled: May 10, 2012Date of Patent: August 11, 2015Assignee: E. R. Squibb & Sons, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
-
Publication number: 20150035762Abstract: An electronic device and a pairing method including following steps are provided. A first touch operation performed on a first touch unit of a first electronic device is detected, and a first azimuth angle of a first pointing direction (defined by the first touch operation) with respect to a reference direction is obtained. The first azimuth angle is compared with a second azimuth angle to obtain an included angle between the first pointing direction and a second pointing direction. When a value obtained by subtracting 180 degrees from an absolute value of the included angle is smaller than a threshold, a pairing relationship is established between the first and second electronic devices. The second azimuth angle is an azimuth angle of the second pointing direction (defined by a second touch operation performed on a second touch unit of the second electronic device) with respect to the reference direction.Type: ApplicationFiled: January 28, 2014Publication date: February 5, 2015Applicant: WINTEK CORPORATIONInventor: Li-Sheng Lu
-
Publication number: 20140186892Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
-
Publication number: 20140134180Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: MEDAREX, L.L.C.Inventors: ALAN J. KORMAN, MARK J. SELBY, LI-SHENG LU, ALISON J. WITTE, HAICHUN HUANG
-
Patent number: 8680247Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.Type: GrantFiled: July 17, 2008Date of Patent: March 25, 2014Assignee: Medarex, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
-
Publication number: 20130339444Abstract: Electronic data exchange system includes a transmitting portable electronic device and a server. The transmitting portable electronic device has an application program. A user of the transmitting portable electronic device utilizes the application program to generate an electronic data transmission control command. The server includes a data base. The data base stores an electronic data album of the user. When the server transmits electronic data of the user to at least one receiving portable electronic device, and transmits electronic data of at least one user of the at least one receiving portable electronic device to the transmitting portable electronic device according to the electronic data transmission control command, the server updates the electronic data album according to the electronic data of the at least one user.Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Inventors: Ming-Chuan Lin, Wen-Hung Wang, Hsuan-Kuang Chen, Li-Sheng Lu, Yuan-Siang Song, Wen-Hsin Wang
-
Patent number: 8609816Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: GrantFiled: December 8, 2006Date of Patent: December 17, 2013Assignee: Medarex, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison Witte, Haichun Huang
-
Publication number: 20120219557Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: MEDAREX, INC.Inventors: Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
-
Publication number: 20120207764Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: ApplicationFiled: April 9, 2012Publication date: August 16, 2012Applicant: MEDAREX, INC.Inventors: Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
-
Patent number: 8222375Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.Type: GrantFiled: December 8, 2006Date of Patent: July 17, 2012Assignee: MEDAREX, Inc.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia